A retrospective study examined 12-month weight loss results comparing sleeve gastrectomy (SG) and tirzepatide in a diverse, urban patient population. The study evaluated changes in BMI, excess weight loss, and total weight loss (TWL) percentage at 3, 6, and 12 months, adhering to ASMBS reporting standards. Linear mixed models demonstrated statistically significant differences in weight loss between the SG and tirzepatide cohorts across all measured time points. The SG cohort experienced a greater BMI reduction, achieving 12% TWL and 7 kg/m2 weight loss at 12 months, compared to the tirzepatide cohort which showed a 2% BMI reduction. This indicates a more substantial weight loss effect with SG compared to tirzepatide within this specific patient group. The study highlights the continued effectiveness of metabolic and bariatric surgery as a method for achieving significant weight loss. The research was conducted within a single center. The findings contribute to the understanding of comparative outcomes between surgical and pharmacological interventions for severe obesity. The study’s focus on a diverse patient population is intended to improve the generalizability of the results. Individualized treatment decisions remain important, considering patient preference, cost, and specific metabolic goals. The research emphasizes the importance of ongoing investigation into obesity treatment options.